🇺🇸 FDA

Company profile · Sponsor

Cullinan

Cullinan Therapeutics

CGEM · NYSE biotech CAMBRIDGE, MA, USA
Pipeline
16
Drugs
0
Patents
3

Quick answer

Cullinan (CGEM) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 0 drugs, and 3 patents to this profile..

Company facts

Ticker CGEM
Exchange NYSE
Company type biotech
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001789972

Pipeline (16)

Search pipeline →

  1. CLN-081

    Cullinan

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. CLN-081, CLN-081

    Cullinan

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 2 small molecule active

    1 trial

  3. VK-2019

    Cullinan

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)

    Cullinan

    Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)

    phase 1 other active

    1 trial

  5. A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

    Cullinan

    Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer

    phase 1 other active

    1 trial

  6. A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

    Cullinan

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  7. A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease

    Cullinan

    Sjogren's Disease

    phase 1 other active

    1 trial

  8. A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)

    Cullinan

    Treatment-Refractory Rheumatoid Arthritis

    phase 1 other active

    1 trial

  9. CLN-049

    Cullinan

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  10. CLN-617

    Cullinan

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  11. CLN-619

    Cullinan

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  12. CLN-619

    Cullinan

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  13. CLN-978

    Cullinan

    NHL

    phase 1 small molecule active

    1 trial

  14. CLN-978

    Cullinan

    Rheumatoid Arthritis (RA

    phase 1 small molecule active

    1 trial

  15. CLN-978

    Cullinan

    Sjögren

    phase 1 small molecule active

    1 trial

  16. CLN-978

    Cullinan

    SLE

    phase 1 small molecule active

    1 trial

Patents (3)

Search patents →

  1. US 12428480

    Anti-CD19 antibodies and multi-specific binding proteins

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12404328

    Multi-specific binding proteins and methods of use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12065493

    Anti-MICA/B antibodies that block MICA/B shedding and methods of use

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Cullinan?

Cullinan (CGEM) is a biotech company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 0 drugs, and 3 patents to this profile..

What pipeline programs does Cullinan sponsor?

We track 16 ClinicalTrials.gov-linked programs for Cullinan, including CLN-081 and 15 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cullinan company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.